Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

ARCA Biopharma Inc (ABIO) USD0.001

Sell:$5.02 Buy:$5.28 Change: $0.04 (0.78%)
NASDAQ:0.05%
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
Sell:$5.02
Buy:$5.28
Change: $0.04 (0.78%)
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
Sell:$5.02
Buy:$5.28
Change: $0.04 (0.78%)
Market closed |  Prices as at close on 13 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Contact details

Address:
11080 Circle Point Rd Ste 140
WESTMINSTER
80020-2769
United States
Telephone:
+1 (720) 9402200
Website:
arcabio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ABIO
ISIN:
US00211Y5069
Market cap:
$8.23 million
Shares in issue:
1.59 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Robert Conway
    Chairman of the Board
  • Michael Bristow
    President, Chief Executive Officer, Director
  • Thomas Keuer
    Chief Operating Officer
  • Christopher Ozeroff
    Senior Vice President, General Counsel, Secretary
  • Brian Selby
    Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.